Thymalin

Background

Thymalin is a thymic peptide complex prepared as a polypeptide extract from calf (bovine) thymus tissue and is classified as a thymic peptide immunomodulator.[13][14] It has been used clinically in the former Soviet Union and Russian Federation since the 1970s–1980s as an injectable biologic for immunodeficiency states, hematologic disorders, and as an adjunct in oncology and infectious diseases.[13] Reported synonyms and closely related products in the Russian literature include “thymic extract,” “thymic polypeptide complex,” and related short-peptide drugs such as Thymogen (EW dipeptide) and Livagen (KE dipeptide), which correspond to active components of Thymalin.[13][14]

Thymalin belongs to a broader class of thymus-derived peptide preparations that emerged from early work on thymic hormones such as thymosin and thymulin.[13] Unlike single defined peptides, Thymalin is a heterogeneous mixture of low–molecular weight peptides (generally <5 kDa) obtained by controlled proteolysis of thymic proteins and subsequent fractionation.[13] The preparation is typically supplied as a lyophilized powder for parenteral use.

Mechanism of action

Thymalin is considered an immunomodulatory rather than a purely immunostimulatory agent, with effects primarily on T‑cell differentiation, proliferation, and functional activity, along with secondary effects on other leukocyte populations.[13][14]

Molecular and cellular targets

Biochemical and molecular studies indicate that:

• Thymalin contains short peptides, notably the dipeptides Lys‑Glu (KE) and Glu‑Trp (EW), which have been identified as key active components.[13][14]
• KE and EW peptides modulate gene expression in immune and inflammatory pathways. In a detailed transcriptomic and proteomic study using human peripheral blood mononuclear cells (PBMCs), KE and EW influenced expression of:
  • ACE2 and CYSLTR1 (primary targets for EW), and
  • CHUK (IKK‑α; primary target for KE).[14][15]
• Protein products of ACE2, CYSLTR1, and CHUK are functionally linked to pathways regulating pro‑ and anti‑inflammatory cytokines including IL‑1β, IL‑6, TNF‑α, IL‑4, and IL‑10.[14][15]

In vitro, Thymalin and its KE/EW components reduced synthesis of IL‑1β, IL‑6, and TNF‑α in human PBMCs under inflammatory conditions, supporting a role in down‑regulation of excessive cytokine responses and potential mitigation of “cytokine storm.”[14][15]

At the cellular level, preclinical and clinical observations suggest that Thymalin:

• Promotes maturation of T lymphocytes from precursor pools and partially restores CD3+, CD4+, and CD8+ populations in immunodeficient states.[13]
• Normalizes T‑cell functional parameters, including delayed‑type hypersensitivity and lymphocyte proliferative responses.[13]
• Favors restoration of hematopoiesis, improving leukocyte and platelet counts after cytotoxic chemotherapy or radiation.[13]

These effects are interpreted as a partial replacement of deficient thymic regulatory signals in conditions characterized by thymic involution, immunosenescence, or iatrogenic immunosuppression.[13]

Evidence summary

Molecular and mechanistic studies

A 2023–2024 integrated molecular study analyzed KE and EW dipeptides within Thymalin using gene expression profiling, molecular docking, and protein–protein interaction analyses.[14][15] The authors demonstrated that:

• EW peptide interacts with ACE2 and CYSLTR1 gene networks, whereas KE interacts with CHUK.[14][15]
• Thymalin and its peptides reduce transcription and secretion of IL‑1β, IL‑6, and TNF‑α in PBMCs stimulated to mimic COVID‑19–related inflammation.[14][15]

These data support a mechanistic basis for previously reported anti‑inflammatory and immunocorrective actions.

Clinical and preclinical data (legacy uses)

Most Thymalin studies originate from Soviet and Russian literature and include heterogeneous designs (open-label, non‑randomized, or small randomized trials). Many reports are older and not indexed in major Western databases; Khavinson’s 2021 review summarizes these data.[13] Key reported areas:

• Immunodeficiency and secondary immunosuppression: Thymalin was used in patients with secondary immunodeficiency, chronic infections, and postoperative or post‑radiation immunodepression, with reported improvements in T‑cell subsets and reduced infection rates.[13]
• Hematologic recovery: In patients undergoing chemotherapy or radiotherapy, Thymalin reportedly accelerated normalization of leukocyte counts and reduced infectious and hemorrhagic complications.[13]
• Pulmonary and critical care settings: Historical data cited in the COVID‑19–related work describe benefit in acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD), though detailed trial documentation is limited.[14]

Because many of these studies predate contemporary trial standards, precise sample sizes, randomization methods, and primary endpoints are not consistently reported in accessible English‑language sources.[13]

COVID‑19 and severe respiratory infection

1. In vitro and molecular analysis (no clinical sample size): The KE/EW study used PBMCs from healthy donors to model inflammatory responses relevant to COVID‑19 and showed that Thymalin and its dipeptides suppressed IL‑1β, IL‑6, and TNF‑α synthesis, implicating modulation of ACE2, CYSLTR1, and CHUK pathways.[14][15]

2. Case report in severe COVID‑19: A 2021 case report described a patient with severe COVID‑19 pneumonia initially treated with lopinavir/ritonavir plus hydroxychloroquine without clinical benefit; subsequent addition of Thymalin was temporally associated with “impressive clinical and laboratory improvement.”[12] This is a single‑patient observation without a control group and cannot establish causality.[12]

3. Narrative review: Khavinson (2021) discusses the use of Thymalin and related peptides as potential adjunctive therapy in COVID‑19, largely based on mechanistic rationale, earlier ARDS/COPD data, and in vitro cytokine‑modulating effects.[13]

Overall, robust randomized controlled trials in COVID‑19 or other modern indications have not been documented in major clinical trial registries as of the latest accessible data. Evidence remains largely preclinical, observational, or based on small, older trials.

Clinical and research uses

Established and historical uses (primarily Russia and some CIS countries)

According to reviews of Russian clinical practice, Thymalin has been used for:[13][14]

• Secondary immunodeficiency of various etiologies (chronic infections, postoperative states, post‑radiation or post‑chemotherapy immunosuppression).
• Oncology as an adjunct to chemo‑ and radiotherapy, aiming to correct immunodepression and improve hematologic recovery.[13]
• Chronic and acute respiratory diseases, including COPD and ARDS, as part of complex therapy to modulate immune responses.[13][14]
• Elderly patients with immunosenescence, aiming to improve immune parameters and resistance to infections.[13]

Usage patterns and indications are derived from national formularies and institutional protocols rather than harmonized international guidelines. These uses are not recognized in US/EU labeling.

Investigational and off‑label research areas

• COVID‑19 and severe viral pneumonia: Thymalin has been proposed as an adjunctive immunomodulator to reduce hyperinflammation and improve outcomes; current evidence is limited to in vitro work, narrative reviews, and isolated case reporting.[12][14][15]
• Inflammatory and fibrotic conditions: On the basis of the KE/EW pathways (ACE2, CYSLTR1, CHUK), Thymalin is being explored conceptually for conditions characterized by dysregulated cytokine production and fibrosis, but controlled clinical data are lacking.[14][15]

There are no registered phase 3 trials of Thymalin in major international registries such as ClinicalTrials.gov at the time of the available literature review.

Dosing context

The following information summarizes regimens reported in the literature and does not constitute dosing recommendations.

Russian‑language sources and reviews describe Thymalin as a parenteral formulation (intramuscular or subcutaneous) administered in short courses, typically:[13]

• Daily injections over 5–10 days, sometimes extended or repeated after intervals, depending on indication.
• Fixed per‑course regimens tailored to body weight or age groups in national guidance (details often not fully specified in English‑language summaries).[13]

For COVID‑19–associated severe pneumonia, the case report notes Thymalin was added as part of intensive care management, but the article does not provide a fully standardized dose schema and focuses primarily on the clinical evolution of a single patient.[12]

Because published English‑language reports lack harmonized dose–response data, the optimal dose, course duration, and long‑term maintenance strategies remain insufficiently characterized in internationally accessible literature.

Safety profile

Khavinson’s 2021 review states that Thymalin and Thymogen (EW dipeptide) have “practically no side effects” based on decades of clinical use in Russia.[13] Reported tolerability features include:[13]

• Good systemic tolerability in short courses.
• Absence of significant allergic or anaphylactic reactions in routine practice, although detailed pharmacovigilance statistics are not provided.

However, systematic safety data according to modern standards (large prospective cohorts, standardized adverse‑event reporting, long‑term follow‑up) are limited. Potential theoretical concerns include:

• Immunologic effects: As an immunomodulator influencing T‑cell function and cytokine profiles, there is a theoretical risk of inappropriate immune activation or suppression in susceptible individuals, although this has not been clearly documented in available reports.[13][14]
• Biologic origin: Being a bovine‑tissue extract, there is a general concern for biological products regarding transmissible agents; manufacturing standards in Russia are designed to mitigate this risk, but detailed viral and prion safety testing data in internationally peer‑reviewed form are scarce.

No clear signal of organ‑specific toxicity, carcinogenicity, or teratogenicity has been published in accessible peer‑reviewed sources. Absence of evidence, particularly for chronic use, should not be interpreted as definitive evidence of safety.

Contraindications and precautions (reported context)

Russian formularies traditionally list contraindications such as individual hypersensitivity to thymic peptides or excipients; detailed contraindication lists are not consistently available in English‑language peer‑reviewed publications.[13] Use during pregnancy, lactation, and in pediatric populations has not been characterized by modern regulatory‑grade studies; caution is generally advised in these groups.

Regulatory status

• United States: Thymalin is not approved by the US Food and Drug Administration (FDA) as a drug or biologic. It does not appear in FDA‑approved product lists, and there is no publicly available Biologics License Application (BLA) or New Drug Application (NDA) referencing a thymic polypeptide complex under the name Thymalin.
• European Union: There is no EMA‑authorized medicinal product corresponding to Thymalin as a thymic polypeptide complex. It is absent from the European public assessment reports and centralized, decentralized, or mutual‑recognition product lists.
• Russia and some CIS countries: Thymalin has been licensed and used as an immunomodulatory peptide drug for several decades, as summarized in Russian‑language reviews and national practice descriptions.[13]

Accordingly, in US and EU jurisdictions Thymalin should be regarded as a non‑approved, non‑standard therapy, and its clinical use would generally be confined to research settings or unregulated importation outside formal regulatory frameworks.